Fig. 2. A comparison of the number of bleeding episodes that needed treatment and of the medical costs between the previous 1 year (conventional therapy using bypassing agents) and the present 1 year (emicizumab prophylaxis) in a Korean pediatric patient with severe hemophilia A and high titer inhibitor.

© Blood Research